SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Thomas E. Glover, Christopher J.E. Watson, Paul Gibbs, J. Andrew Bradley, Evangelia E. Ntzani, Vasilis Kosmoliaptsis, Conversion From Calcineurin to Mammalian Target of Rapamycin Inhibitors in Liver Transplantation, Transplantation, 2016, 100, 3, 621

    CrossRef

  2. 2
    EASL Clinical Practice Guidelines: Liver transplantation, Journal of Hepatology, 2016, 64, 2, 433

    CrossRef

  3. 3
    Ying-Yu Huang, Chia-Chen Hsu, Chia-Lin Chou, Che-Chuan Loong, Min-Shan Wu, Yueh-Ching Chou, Trends in the use of maintenance immunosuppressive drugs among liver transplant recipients in Taiwan: a nationwide population-based study, Pharmacoepidemiology and Drug Safety, 2016, 25, 5
  4. 4
    Greg J. McKenna, Goran B.G. Klintmalm, Molecules to Medicine with mTOR, 2016,

    CrossRef

  5. 5
    M. Shah, A. Shankar, I. Gee, K. Nash, M. Hoare, P. Gibbs, S. Davies, G. J. M. Alexander, A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients, Alimentary Pharmacology & Therapeutics, 2015, 41, 4
  6. 6
    C. Dopazo, I. Bilbao, L. L. Castells, G. Sapisochin, C. Moreiras, I. Campos-Varela, J. Echeverri, M. Caralt, J. L. Lázaro, R. Charco, Analysis of adult 20-year survivors after liver transplantation, Hepatology International, 2015, 9, 3, 461

    CrossRef

  7. 7
    Andreas A. Schnitzbauer, Johannes Sothmann, Lucia Baier, Thomas Bein, Edward K. Geissler, Marcus N. Scherer, Hans J. Schlitt, Calcineurin Inhibitor Free De Novo Immunosuppression in Liver Transplant Recipients With Pretransplant Renal Impairment, Transplantation, 2015, 99, 12, 2565

    CrossRef

  8. 8
    Geoffrey W McCaughan, Kenny Ching Pan Sze, Simone I Strasser, Is there such a thing as protocol immunosuppression in liver transplantation?, Expert Review of Gastroenterology & Hepatology, 2015, 9, 1, 1

    CrossRef

  9. 9
    Hallvard Holdaas, Luciano Potena, Faouzi Saliba, mTOR inhibitors and dyslipidemia in transplant recipients: A cause for concern?, Transplantation Reviews, 2015, 29, 2, 93

    CrossRef

  10. 10
    Benjamin T. Duhart, Winston A. Ally, Amy G. Krauss, Joanna Q. Hudson, James D. Eason, Vinaya Rao, Jason M. Vanatta, The Benefit of Sirolimus Maintenance Immunosuppression and Rabbit Antithymocyte Globulin Induction in Liver Transplant Recipients That Develop Acute Kidney Injury in the Early Postoperative Period, Journal of Transplantation, 2015, 2015, 1

    CrossRef

  11. 11
    Fernando Pardo, José Antonio Pons, Javier Briceño, V Consensus Meeting of the Spanish Society for Liver Transplant on High-Risk Recipients, Immunosupression Scenarios and Management of Hepatocarcinoma on the Transplant Waiting List, Cirugía Española (English Edition), 2015, 93, 10, 619

    CrossRef

  12. 12
    Fernando Pardo, José Antonio Pons, Javier Briceño, V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante, Gastroenterología y Hepatología, 2015, 38, 10, 600

    CrossRef

  13. 13
    Fernando Pardo, José Antonio Pons, Javier Briceño, V Reunión de Consenso de la Sociedad Española de Trasplante Hepático sobre receptores de riesgo elevado, escenarios actuales de inmunosupresión y manejo del hepatocarcinoma en espera de trasplante, Cirugía Española, 2015, 93, 10, 619

    CrossRef

  14. 14
    Juan F. Gallegos-Orozco, Jeffrey Campsen, Transplantation of the Liver, 2015,

    CrossRef

  15. 15
    Greg J. McKenna, Göran B.G. Klintmalm, Transplantation of the Liver, 2015,

    CrossRef

  16. 16
    Jacqueline G. O’Leary, James F. Trotter, Transplantation of the Liver, 2015,

    CrossRef

  17. 17
    Phuong-Thu T. Pham, Chong Parke, Reza Allamezadeh, Phuong-Chi T. Pham, Gabriel M. Danovitch, Transplantation of the Liver, 2015,

    CrossRef

  18. 18
    Sebastian Fischer, Christine G. Lian, Maximilian Kueckelhaus, Terry B. Strom, Elazer R. Edelman, Rachel A. Clark, George F. Murphy, Anil K. Chandraker, Leonardo V. Riella, Stefan G. Tullius, Bohdan Pomahac, Acute rejection in vascularized composite allotransplantation, Current Opinion in Organ Transplantation, 2014, 19, 6, 531

    CrossRef

  19. 19
    Daniel Nils Gotthardt, Helge Bruns, Karl Heinz Weiss, Peter Schemmer, Current strategies for immunosuppression following liver transplantation, Langenbeck's Archives of Surgery, 2014, 399, 8, 981

    CrossRef

  20. 20
    S. K. Asrani, R. H. Wiesner, J. F. Trotter, G. Klintmalm, E. Katz, E. Maller, J. Roberts, N. Kneteman, L. Teperman, J. J. Fung, J. M. Millis, De Novo Sirolimus and Reduced-Dose Tacrolimus Versus Standard-Dose Tacrolimus After Liver Transplantation: The 2000–2003 Phase II Prospective Randomized Trial, American Journal of Transplantation, 2014, 14, 2
  21. 21
    M. Sterneck, G. M. Kaiser, N. Heyne, N. Richter, F. Rauchfuss, A. Pascher, P. Schemmer, L. Fischer, C. G. Klein, S. Nadalin, F. Lehner, U. Settmacher, P. Neuhaus, D. Gotthardt, M. Loss, S. Ladenburger, E. M. Paulus, M. Mertens, H. J. Schlitt, Everolimus and Early Calcineurin Inhibitor Withdrawal: 3-Year Results From a Randomized Trial in Liver Transplantation, American Journal of Transplantation, 2014, 14, 3
  22. 22
    Federico G. Villamil, Adrian C. Gadano, Fernanda Zingale, Roberto Perez, Octavio Gil, Silvina Yantorno, Ricardo Mastai, Fernando O. Cairo, Alcira B. Otero, Gaohong Dong, Patricia Lopez, Fibrosis progression in maintenance liver transplant patients with hepatitis C recurrence: a randomised study of everolimus vs. calcineurin inhibitors, Liver International, 2014, 34, 10
  23. 23
    Paige M. Porrett, Sohaib K. Hashmi, Abraham Shaked, Immunosuppression, Clinics in Liver Disease, 2014, 18, 3, 687

    CrossRef

  24. 24
    Goran B. Klintmalm, Björn Nashan, The Role of mTOR Inhibitors in Liver Transplantation: Reviewing the Evidence, Journal of Transplantation, 2014, 2014, 1

    CrossRef

  25. 25
    Lewis Teperman, Dilip Moonka, Anthony Sebastian, Linda Sher, Paul Marotta, Christopher Marsh, Baburao Koneru, John Goss, Dennis Preston, John P. Roberts, Calcineurin Inhibitor–Free Mycophenolate Mofetil/Sirolimus Maintenance in Liver Transplantation: The Randomized Spare-the-Nephron Trial, Liver Transplantation, 2013, 19, 7
  26. 26
    Susanne Beckebaum, Vito R. Cicinnati, Arnold Radtke, Iyad Kabar, Calcineurin inhibitors in liver transplantation – still champions or threatened by serious competitors?, Liver International, 2013, 33, 5
  27. 27
    James F. Trotter, Monica Grafals, Angel E. Alsina, Early use of renal-sparing agents in liver transplantation: A closer look, Liver Transplantation, 2013, 19, 8
  28. 28
    Maria-Carlota Londoño, Antoni Rimola, John O’Grady, Alberto Sanchez-Fueyo, Immunosuppression minimization vs. complete drug withdrawal in liver transplantation, Journal of Hepatology, 2013, 59, 4, 872

    CrossRef

  29. 29
    T. Isakova, H. Xie, S. Messinger, F. Cortazar, J. J. Scialla, G. Guerra, G. Contreras, D. Roth, G. W. Burke, M. Z. Molnar, I. Mucsi, M. Wolf, Inhibitors of mTOR and Risks of Allograft Failure and Mortality in Kidney Transplantation, American Journal of Transplantation, 2013, 13, 1
  30. 30
    Nada A. Yazigi, Long Term Outcomes after Pediatric Liver Transplantation, Pediatric Gastroenterology, Hepatology & Nutrition, 2013, 16, 4, 207

    CrossRef

  31. 31
    Josh Levitsky, Gabriel C. Oniscu, Meeting report of the international liver transplantation society's 18th annual international congress: Hilton San Francisco Hotel, San Francisco, CA, May 16-19, 2012, Liver Transplantation, 2013, 19, 1
  32. 32
    Martin-Walter Welker, Wolf-Otto Bechstein, Stefan Zeuzem, Joerg Trojan, Recurrent hepatocellular carcinoma after liver transplantation – an emerging clinical challenge, Transplant International, 2013, 26, 2
  33. 33
    Michael R. Charlton, Sirolimus as a calcineurin inhibitor– and renal-sparing agent: All good things come to those who wait versus spare the nephron, spoil the patient, Liver Transplantation, 2013, 19, 8
  34. 34
    L. Fischer, J. Klempnauer, S. Beckebaum, H. J. Metselaar, P. Neuhaus, P. Schemmer, U. Settmacher, N. Heyne, P-A. Clavien, F. Muehlbacher, I. Morard, H. Wolters, W. Vogel, T. Becker, M. Sterneck, F. Lehner, C. Klein, G. Kazemier, A. Pascher, J. Schmidt, F. Rauchfuss, A. Schnitzbauer, S. Nadalin, M. Hack, S. Ladenburger, H. J. Schlitt, A Randomized, Controlled Study to Assess the Conversion From Calcineurin-Inhibitors to Everolimus After Liver Transplantation—PROTECT, American Journal of Transplantation, 2012, 12, 7
  35. 35
    Praveen Kandula, Jonathan Fridell, Tim E. Taber, Asif Sharfuddin, Muhammad S. Yaqub, Carrie L. Phillips, Jeannie Chen, Muhammad Mujtaba, Impact of Tacrolimus-Sirolimus Maintenance Immunosuppression on Proteinuria and Kidney Function in Pancreas Transplant Alone Recipients, Transplantation Journal, 2012, 94, 9, 940

    CrossRef

  36. 36
    Maxime Touzot, Jean Paul Soulillou, Jacques Dantal, Mechanistic target of rapamycin inhibitors in solid organ transplantation, Current Opinion in Organ Transplantation, 2012, 17, 6, 626

    CrossRef

  37. 37
    James Trotter, Ben Kahn, Renal dysfunction and the liver transplant recipient; novel strategies for determination of reversibility and renal protective therapies pretransplant and posttransplant, Current Opinion in Organ Transplantation, 2012, 17, 3, 225

    CrossRef

  38. 38
    G. J. McKenna, J. F. Trotter, Sirolimus Conversion for Renal Dysfunction in Liver Transplant Recipients: The Devil Really Is in the Details…, American Journal of Transplantation, 2012, 12, 3
  39. 39
    Winston A. Ally, Avinash Agarwal, Drugs Specifically Approved for Transplant Indications,